Carboplatin
- Generic Name
- Carboplatin
- Brand Names
- Paraplatin
- Drug Type
- Small Molecule
- Chemical Formula
- C6H12N2O4Pt
- CAS Number
- 41575-94-4
- Unique Ingredient Identifier
- BG3F62OND5
- Background
Carboplatin is an organoplatinum antineoplastic alkylating agent used in the treatment of advanced ovarian carcinoma. Early clinical studies of carboplatin were performed in 1982. Carboplatin was developed as an analog of cisplatin with reduced nephrotoxicity and vomiting.
Carboplatin was granted FDA approval on 3 March 1989.
- Indication
Carboplatin is indicated in combination with an established combination of chemotherapeutic agents for the initial treatment of advanced ovarian carcinoma. Carboplatin is also indicated for the palliative treatment of ovarian carcinoma, recurrent after prior chemotherapy.
- Associated Conditions
- Advanced Cervical Cancer, Advanced Endometrial Cancer, Advanced Esophageal Cancers, Advanced Head and Neck Cancer, Advanced Melanoma, Advanced Non-Small Cell Lung Cancer (NSCLC), Advanced Ovarian Carcinoma, Advanced Sarcoma, Malignant Pleural Mesothelioma (MPM), Merkel Cell Carcinoma, Metastatic Breast Cancer, Refractory Hodgkin Lymphoma, Retinoblastoma, Thymoma, Advanced Bladder cancer, Advanced Small cell lung cancer, Advanced Testicular cancer, Advanced Thymoma, Refractory Non-Hodgkin's lymphoma
- Associated Therapies
- Conditioning regimens for allogeneic stem cell transplantation therapy
A Dose Escalation Study of Adavosertib (MK-1775) in Combination With Either Gemcitabine, Cisplatin, or Carboplatin in Adults With Advanced Solid Tumors (MK-1775-001)
- Conditions
- Solid Tumors
- Interventions
- First Posted Date
- 2008-04-01
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 206
- Registration Number
- NCT00648648
Cetuximab, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer That Cannot Be Removed By Surgery
- Conditions
- Head and Neck Cancer
- First Posted Date
- 2008-03-28
- Last Posted Date
- 2018-07-09
- Lead Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
- Target Recruit Count
- 47
- Registration Number
- NCT00646659
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Carboplatin, Abraxane, and Bevacizumab in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2008-03-25
- Last Posted Date
- 2017-04-07
- Lead Sponsor
- Massachusetts General Hospital
- Target Recruit Count
- 36
- Registration Number
- NCT00642759
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Conditions
- Adult Acute Myeloblastic Leukemia Without Maturation (M1)Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myelomonocytic Leukemia (M4)Adult Acute Myeloblastic Leukemia With Maturation (M2)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Monoblastic Leukemia (M5a)Adult Acute Monocytic Leukemia (M5b)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Recurrent Adult Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2008-03-12
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 92
- Registration Number
- NCT00634244
- Locations
- 🇺🇸
Northwestern University, Chicago, Illinois, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Mayo Clinic in Florida, Jacksonville, Florida, United States
Radiation Therapy Regimens in Treating Patients With Limited-Stage Small Cell Lung Cancer Receiving Cisplatin and Etoposide
- Conditions
- Lung Cancer
- Interventions
- Radiation: Standard Radiation Dose TherapyDrug: cisplatinDrug: etoposideRadiation: High Radiation Dose TherapyDrug: carboplatin
- First Posted Date
- 2008-03-11
- Last Posted Date
- 2023-06-12
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 731
- Registration Number
- NCT00632853
- Locations
- 🇺🇸
Saint Mary Corwin Medical Center, Pueblo, Colorado, United States
🇺🇸NorthShore University HealthSystem-Glenbrook Hospital, Glenview, Illinois, United States
🇺🇸Illinois CancerCare-Princeton, Princeton, Illinois, United States
Bevacizumab and Temozolomide or Bevacizumab and Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Carboplatin in Treating Patients With Stage IV Malignant Melanoma That Cannot Be Removed by Surgery
- Conditions
- Melanoma (Skin)
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2018-05-01
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 95
- Registration Number
- NCT00626405
- Locations
- 🇺🇸
Swedish Medical Center, Englewood, Colorado, United States
🇺🇸Perry Memorial Hospital, Princeton, Illinois, United States
🇺🇸St. James Healthcare Cancer Care, Butte, Montana, United States
BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2020-09-10
- Lead Sponsor
- NSABP Foundation Inc
- Target Recruit Count
- 3509
- Registration Number
- NCT00625898
- Locations
- 🇺🇸
Peninsula Regional Oncology & Hematology, Salisbury, Maryland, United States
🇺🇸Associates in Oncology/Hematology, Rockville, Maryland, United States
🇺🇸The Office of Frederik Smith, Chevy Chase, Maryland, United States
MnSOD (Esophageal Protectant) to Prevent Esophagitis During Radiation/Chemotherapy Treatment for Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- EsophagealToxicity
- Interventions
- Genetic: Manganese Superoxide Dismutase Plasmid LiposomeDrug: carboplatinDrug: paclitaxelRadiation: Radiation Therapy
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2021-11-12
- Lead Sponsor
- Joel Greenberger
- Target Recruit Count
- 18
- Registration Number
- NCT00618917
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting
- Conditions
- HER2-negative Breast CancerStage IIIB Breast CancerBreast CancerStage IB Breast CancerStage IIIA Breast CancerStage II Breast CancerStage IIIC Breast CancerHER2-positive Breast CancerRecurrent Breast CancerStage IA Breast Cancer
- Interventions
- Drug: CarboplatinDrug: paclitaxel albumin-stabilized nanoparticle formulationDrug: trastuzumabDrug: bevacizumabProcedure: magnetic resonance imagingProcedure: therapeutic conventional surgery
- First Posted Date
- 2008-02-20
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University of California, Irvine
- Target Recruit Count
- 127
- Registration Number
- NCT00618657
- Locations
- 🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-02-15
- Last Posted Date
- 2024-02-07
- Lead Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Target Recruit Count
- 68
- Registration Number
- NCT00616967
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸University of Alabama Comprehensive Cancer Center, Birmingham, Alabama, United States
🇺🇸Indiana University Purdue University of Indianapolis, Indianapolis, Indiana, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.